#1 Clinical Trials Search in Europe

Gfh925

GFH925 is an innovative drug currently being studied in clinical trials for patients with advanced solid tumors, particularly those with KRAS G12C mutations. These trials aim to evaluate the safety, effectiveness, and optimal dosing of GFH925 in treating various types of cancer, including non-small cell lung cancer (NSCLC) and colorectal cancer. The studies also explore the potential of combining GFH925 with other treatments to improve patient outcomes.

Table of Contents

What is GFH925?

GFH925 is a new drug being studied for its potential to treat certain types of cancer[1]. It is specifically designed to target cancers that have a particular genetic mutation called KRAS G12C. This mutation is found in some types of lung cancer and other solid tumors, and it can make these cancers particularly difficult to treat with existing therapies.

What Conditions Does GFH925 Target?

GFH925 is being investigated for the treatment of several conditions, including:

  • Advanced Non-small Cell Lung Cancer (NSCLC): This is a type of lung cancer that is the most common form of the disease. GFH925 is being studied in patients with advanced NSCLC that carries the KRAS G12C mutation[2].
  • Advanced Colorectal Cancer: This is cancer that starts in the colon or rectum and has spread to other parts of the body. GFH925 is being tested in patients with this type of cancer that have the KRAS G12C mutation[1].
  • Other Advanced Solid Tumors: The drug is also being studied in patients with various other types of solid tumors that have the KRAS G12C mutation[1].

How is GFH925 Administered?

GFH925 is administered as an oral tablet that patients take daily[2][1]. This means that patients can take the medication at home, which can be more convenient than treatments that require frequent hospital visits for intravenous administration.

Current Clinical Trials

GFH925 is currently being studied in several clinical trials:

  1. Phase I/II Trial for Advanced Solid Tumors: This study is evaluating the safety, tolerability, and effectiveness of GFH925 in patients with advanced solid tumors that have the KRAS G12C mutation. It includes separate phases for dose escalation, dose expansion, and efficacy evaluation in specific cancer types[1].
  2. Phase Ib/II Trial in Combination with Cetuximab: This study is looking at the combination of GFH925 with another drug called cetuximab in patients with previously untreated advanced NSCLC that has the KRAS G12C mutation[2].

Combination Therapy with Cetuximab

One of the clinical trials is studying GFH925 in combination with another drug called cetuximab[2]. Cetuximab is an existing cancer treatment that works differently from GFH925. By combining these two drugs, researchers hope to see if they can improve the effectiveness of treatment for patients with advanced NSCLC that has the KRAS G12C mutation.

Safety and Efficacy Evaluation

The clinical trials for GFH925 are designed to carefully evaluate both the safety and the effectiveness of the drug. Here are some key aspects being studied:

  • Safety: Researchers are closely monitoring for any side effects or adverse events that patients may experience while taking GFH925. This includes tracking changes in laboratory tests, vital signs, and physical examinations[1].
  • Efficacy: The trials are measuring how well GFH925 works against the targeted cancers. This includes looking at the objective response rate (ORR), which is the percentage of patients whose cancer shrinks or disappears after treatment[2][1].
  • Pharmacokinetics: This involves studying how the drug moves through the body, including how quickly it’s absorbed, how it’s distributed, and how long it stays in the system[1].

It’s important to note that while these trials are promising, GFH925 is still an experimental drug. More research is needed to fully understand its benefits and potential risks before it can be approved for general use in cancer treatment.

Aspect Details
Drug Name GFH925
Administration Oral tablet
Target Population Patients with advanced solid tumors harboring KRAS G12C mutations
Cancer Types Studied Non-small cell lung cancer (NSCLC), colorectal cancer, other solid tumors
Study Phases Phase I/II
Primary Objectives Evaluate safety, tolerability, and efficacy; Determine optimal dosing
Secondary Objectives Assess pharmacokinetics, objective response rate, disease control rate, survival outcomes
Combination Therapy GFH925 + Cetuximab (in one study for previously untreated advanced NSCLC)

FAQ

  • What is GFH925 and what types of cancer is it being studied for? GFH925 is an oral medication being investigated for the treatment of advanced solid tumors with KRAS G12C mutations. It is primarily being studied in patients with non-small cell lung cancer (NSCLC) and colorectal cancer, but may also be effective in other types of tumors with the same mutation.
  • How is GFH925 administered to patients in the clinical trials? GFH925 is administered as an oral tablet formulation, which means patients can take it by mouth. The exact dosing schedule may vary depending on the specific trial phase and study design.
  • What are the main goals of the GFH925 clinical trials? The main goals of the GFH925 clinical trials are to evaluate the safety and tolerability of the drug, determine the most effective dose, assess its effectiveness in treating various cancers, and study how the body processes the medication (pharmacokinetics).
  • Are there any combination therapies being studied with GFH925? Yes, one of the clinical trials is studying the combination of GFH925 with Cetuximab in previously untreated advanced NSCLC patients with KRAS G12C mutations. This combination therapy aims to explore potential improved outcomes compared to single-drug treatment.
  • What are some of the key outcomes being measured in these trials? Key outcomes being measured include the incidence and severity of side effects, objective response rate (how well tumors respond to treatment), disease control rate, duration of response, progression-free survival, and overall survival. The trials also assess how the body processes the drug through various blood tests.

Ongoing Clinical Trials on Gfh925

  • Study on the Safety and Effectiveness of GFH925 and Cetuximab for Patients with Advanced Lung Cancer with KRAS G12C Mutation

    Not yet recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France Greece Italy Spain

Glossary

  • KRAS G12C mutation: A specific change in the KRAS gene that can lead to uncontrolled cell growth and cancer. This mutation is found in some types of lung, colorectal, and other cancers.
  • Non-small cell lung cancer (NSCLC): The most common type of lung cancer, accounting for about 80-85% of all cases. It grows and spreads more slowly than small cell lung cancer.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including how it's absorbed, distributed, metabolized, and eliminated.
  • Maximum tolerated dose (MTD): The highest dose of a drug that can be given without causing unacceptable side effects.
  • Recommended Phase 2 dose (RP2D): The dose of a drug determined to be safe and potentially effective, which is then used in further studies to evaluate its effectiveness.
  • Objective response rate (ORR): The percentage of patients whose cancer shrinks or disappears after treatment.
  • Disease control rate (DCR): The percentage of patients whose cancer shrinks, disappears, or remains stable after treatment.
  • Progression-free survival (PFS): The length of time during and after treatment that a patient lives with cancer without it getting worse.
  • Overall survival (OS): The length of time from the start of treatment that patients are still alive.
  • RECIST 1.1: Response Evaluation Criteria in Solid Tumors version 1.1, a standard way to measure how well a cancer patient responds to treatment.
  • Cetuximab: A targeted therapy drug that works by blocking a protein called EGFR, which can help slow or stop the growth of certain types of cancer cells.

References

  1. https://clinicaltrials.gov/study/NCT05005234
  2. https://clinicaltrials.gov/study/NCT05756153